Skip Navigation

European Heart Journal 2001 22(20):1948-1953; doi:10.1053/euhj.2001.2626
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Herrmann, S.-M.
Right arrow Articles by Osterziel, K.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herrmann, S.-M.
Right arrow Articles by Osterziel, K.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy

S.-M. Herrmanna,f1, K. Schmidt-Petersena, J. Pfeifera, A. Perrotb, N. Bit-Avragimb, C. Eichhornb, R. Dietzb, R. Kreutza, M. Paula and K.J. Osterzielb

a Institute of Clinical Pharmacology and Toxicology, Department of Clinical Pharmacology, Benjamin Franklin Medical Center, Freie Universität, Berlin, Germany
b Franz-Volhard-Klinik, Max-Delbrück-Center for Molecular Medicine, Humboldt-Universität, Berlin, Germany

revised January 30, 2001; accepted January 31, 2001

Abstract

Aims The endothelin system plays a role in the complex pathophysiology of idiopathic dilated cardiomyopathy. We investigated whether genetic polymorphisms of the endothelin system might be associated with dilated cardiomyopathy-related cardiac phenotypes and differences in disease outcome.

Methods One hundred and twenty-five unrelated dilated cardiomyopathy patients of a well characterized dilated cardiomyopathy cohort were genotyped for six common polymorphisms of the endothelin-1, endothelin-A (ETA) and endothelin-B (ETB) receptor genes using hybridization with allele-specific oligonucleotides.

Results The H323H (C/T) polymorphism in exon 6 of the ETAreceptor gene was significantly associated with a shorter survival time after diagnosis. The odds ratio for carriers of the less frequent ETAT allele to die within 2 years after diagnosis was 5·5 (95% confidence interval, 1·4 to 21·0, P=0·013) compared to non-carriers. Kaplan–Meier analysis revealed a significantly different survival time for T allele carriers as compared to non-carriers as tested by logrank (P=0·0196), Breslow (P=0·0195), and Tarone tests (P=0·020). The influence of the ETAH323H polymorphism on survival remained significant when known predictors of prognosis such as left ventricular ejection fraction, left ventricular end-diastolic diameter, age and NYHA functional classification were entered in a Cox proportional hazards analysis. In this model, end-diastolic diameter showed a trend to influence survival (P=0·07) but only the ETAH323H polymorphism (P=0·0029) was a significant independent predictor of survival.

Conclusions Our results suggest that genetic variation in the ETAreceptor predicts survival in dilated cardiomyopathy patients, which might have important consequences for the identification of high-risk individuals.

Key Words: Endothelin-A receptor, genetic polymorphism, dilative cardiomyopathy, survival

f1 Correspondence: Stefan-Martin Herrmann, Institute of Clinical Pharmacology and Toxicology, Department of Clinical Pharmacology, Benjamin Franklin Medical Center, Freie Universität Berlin, Hindenburgdamm 30, 12200 Berlin, Germany.

References

  1. Richardson P, McKenna W, Bristow M. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841–842[Free Full Text]
  2. Dec WG, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med. 1994;331:1564–1575[Free Full Text]
  3. Michels VV, Moll PP, Miller FA. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med. 1992;326:77–82[Abstract]
  4. Keeling PJ, Gang Y, Smith G. Familial dilated cardiomyopathy in the United Kingdom. Br Heart J. 1995;73:417–421[Abstract/Free Full Text]
  5. Grünig E, Tasman JA, Kücherer H, Franz W, Kübler W, Katus HA. Frequency and phenotypes of familial dilated cardiomyopathy. J Am Coll Cardiol. 1998;31:186–194[Abstract/Free Full Text]
  6. Hiroe M, Hirata Y, Fujita N. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. Am J Cardiol. 1991;68:1114–1115[CrossRef][Web of Science][Medline]
  7. Mundhenke M, Schwartzkopff B, Köstering M, Deska U, Klein RM, Strauer BE. Endogenous plasma endothelin concentrations and coronary circulation in patients with mild dilated cardiomyopathy. Heart. 1999;81:278–284[Abstract/Free Full Text]
  8. Pieske B, Beyermann B, Breu V. Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium. Circulation. 1999;99:1802–1809[Abstract/Free Full Text]
  9. Zolk O, Quattek J, Sitzler G. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation. 1999;99:2118–2123[Abstract/Free Full Text]
  10. Yanagisawa M, Kurihara H, Kimura S. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415[CrossRef][Medline]
  11. Suzuki T, Kumazaki T, Mitsui Y. Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem Biophys Res Commun. 1993;191:823–830[CrossRef][Web of Science][Medline]
  12. Suzuki T, Tsuruda A, Katoh S, Kubodera A, Mitsui Y. Purification of endothelin from a conditioned medium of cardiac fibroblastic cells using beating rate assay of myocytes cultured in a serum-free medium. J Mol Cell Cardiol. 1997;29:2087–2093[CrossRef][Web of Science][Medline]
  13. Ponicke K, Vogelsang M, Heinroth M. Endothelin receptor in the failing and nonfailing human heart. Circulation. 1998;97:744–751[Abstract/Free Full Text]
  14. Rothermund L, Paul M. The role of endothelin in hypertension. Curr Opin Nephrol Hypertens. 1998;4:451–456
  15. Nicaud V, Poirier O, Behague I. Polymorphisms of the endothelin-A and -B receptor genes in relation to blood pressure and myocardial infarction: the Etude Cas-Temoins sur l'Infarctus du Myocarde (ECTIM) Study. Am J Hypertens. 1999;12:304–310[CrossRef][Web of Science][Medline]
  16. Tiret L, Poirier O, Hallet V. The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. Hypertension. 1999;33:1169–1174[Abstract/Free Full Text]
  17. Charron P, Tesson F, Poirier O. Identification of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene. Eur Heart J. 1999;20:1587–1591[Abstract/Free Full Text]
  18. Osterziel KJ, Strohm O, Schuler J. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet. 1998;351:1233–1237[CrossRef][Web of Science][Medline]
  19. Jung M, Poepping I, Perrot A. Investigation of a family with autosomal dominant dilated cardiomyopathy defines a novel locus on chromosome 2q14-q22. Am J Hum Genet. 1999;65:1068–1077[CrossRef][Web of Science][Medline]
  20. Schiller NB, Shah PM, Crawford M. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2:358–367[Medline]
  21. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072–1083[Abstract/Free Full Text]
  22. Sandler H, Dodge HT. The use of single plane angiocardiograms for the calculation of left ventricular volume in man. Am Heart J. 1968;75:325–334[CrossRef][Web of Science][Medline]
  23. Vasan RS, Larson MG, Levy D, Evans JC, Benjamin EJ. Distribution and categorization of echocardiographic measurements in relation to reference limits: the Framingham Heart Study: formulation of a height- and sex-specific classification and its prospective validation. Circulation. 1997;96:1863–1873[Abstract/Free Full Text]
  24. Herrmann SM, Ricard S, Nicaud V. The P-selectin gene is highly polymorphic: reduced frequency of the Pro715 allele carriers in patients with myocardial infarction. Hum Mol Genet. 1998;7:1277–1284[Abstract/Free Full Text]
  25. Lancet. 1999;353:2001–2007[CrossRef][Web of Science][Medline]
  26. Lancet. 1999;353:9–13[CrossRef][Web of Science][Medline]
  27. Cowburn PJ, Cleland JG, McArthur JD, MacLean MR, McMurray JJ, Dargie HJ. Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure. Lancet. 1998;352:201–202[Web of Science][Medline]
  28. Sutsch G, Kiowski W, Yan XW. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 1998;98:2262–2268[Abstract/Free Full Text]
  29. Kiowski W, Sutsch G, Hunziker P. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;346:732–736[CrossRef][Web of Science][Medline]
  30. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 1996;384:353–355[CrossRef][Medline]
  31. Yamauchi-Kohno R, Miyauchi T, Hoshino T. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function. Circulation. 1999;99:2171–2176[Abstract/Free Full Text]
  32. Mulder P, Richard V, Derumeaux G. Role of endogenous endothelin in chronic heart failure. Circulation. 1997;96:1976–1982[Abstract/Free Full Text]
  33. Fraccarollo D, Hu K, Galuppo P, Gaudron P, Ertl G. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation. 1997;96:3963–3973[Abstract/Free Full Text]
  34. Cannan CR, Burnett JC Jr, Lerman A. Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure. Circulation. 1996;93:646–651[Abstract/Free Full Text]
  35. Love MP, Haynes WG, Gray GA, Webb DJ, McMurray JJ. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETAreceptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation. 1996;94:2131–2137[Abstract/Free Full Text]
  36. Love MP, Haynes WG, Webb DJ, McMurray JJ. Venous endothelin receptor function in patients with chronic heart failure. Clin Sci. 2000;98:65–70[Medline]
  37. N Engl J Med. 1991;325:293–302[Abstract]
  38. N Engl J Med. 1987;316:1429–1435[Abstract]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
H. A. Ghofrani, R. J. Barst, R. L. Benza, H. C. Champion, K. A. Fagan, F. Grimminger, M. Humbert, G. Simonneau, D. J. Stewart, C. Ventura, et al.
Future perspectives for the treatment of pulmonary arterial hypertension.
J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S108 - S117.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
G. Kitsios and E. Zintzaras
Genetic Variation associated with Ischemic Heart Failure: A HuGE Review and Meta-Analysis
Am. J. Epidemiol., September 15, 2007; 166(6): 619 - 633.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. Richard, E. Villard, P. Charron, and R. Isnard
The Genetic Bases of Cardiomyopathies
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A79 - A89.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
P. Le Corvoisier, H.-Y. Park, K. M. Carlson, D. A. Marchuk, and H. A. Rockman
Multiple quantitative trait loci modify the heart failure phenotype in murine cardiomyopathy
Hum. Mol. Genet., December 1, 2003; 12(23): 3097 - 3107.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
W. Kiowski
The endothelin-type-A receptor in dilated cardiomyopathy: another key player?
Eur. Heart J., October 2, 2001; 22(20): 1849 - 1851.
[PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Herrmann, S.-M.
Right arrow Articles by Osterziel, K.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herrmann, S.-M.
Right arrow Articles by Osterziel, K.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?